Koninklijke Phil Stock Price, News & Analysis

Philips has received FDA 510(k) clearance for its Spectral CT 7500 RT, the world's first spectral 4DCT respiratory-gated imaging system for radiation therapy. This innovative technology combines conventional and spectral CT capabilities in a single scan, enabling more precise radiation therapy planning by better visualizing tumor characteristics. The system reduces proton stopping-power ratio error by over 50% compared to conventional CT and creates stopping power ratio maps with less than 1% deviation, significantly improving treatment accuracy while sparing healthy tissue. This advancement allows for more personalized cancer treatment without adding extra steps to existing radiotherapy workflows.

Philips announced enrollment of the first patient in the U.S. THOR IDE clinical trial, testing an innovative combined laser atherectomy and intravascular lithotripsy catheter. The device integrates two PAD treatments into a single solution, performed at the Cardiovascular Institute of the South in Louisiana on a 78-year-old male. The trial will enroll up to 155 patients at up to 30 U.S. sites to evaluate safety and efficacy in treating complex, calcified lesions. The study's primary endpoints include freedom from major adverse events within 30 days and achieving ≤50% residual stenosis post-procedure, with 12-month patient follow-up.

Philips (NYSE: PHG) has announced a partnership with Aspen Dental, bringing Philips Sonicare products to Aspen's network of over 1,100 dental offices. The collaboration will offer patients access to Philips Sonicare ExpertClean toothbrushes, Cordless Power Flossers, and Teeth Whitening Kits. The partnership includes the introduction of Philips' new Path to Health Toolset, developed with behavioral scientists and dental professionals to enhance patient care and education. This initiative aims to expand access to comprehensive oral care and support dental professionals in providing better patient outcomes both in-office and at home.

Philips has secured a $25 million contract with the U.S. Department of Defense to expand its RATE (Rapid Analysis of Threat Exposure) algorithm over the next four years. The AI-powered technology uses biomarkers from wearables for early infection detection in military personnel. RATE's effectiveness was demonstrated in studies, including a 2022 research showing COVID-19 detection 2.3 days before symptoms appeared in 9,381 DoD personnel. The algorithm, initially developed in 2019, analyzed 163 biomarkers from 36,000 hospital-acquired infection cases to develop risk scores for various infections.

Philips (PHG) reported Q3 2024 results with flat comparable sales at EUR 4.4 billion, primarily due to deteriorated demand in China while showing growth in other regions. The company achieved significant margin improvement with Adjusted EBITA margin increasing to 11.8% from 10.2%. Free cash flow was EUR 22 million, and comparable order intake decreased by 2% due to China decline. The company revised its full-year 2024 outlook, projecting comparable sales growth of 0.5-1.5%, with Adjusted EBITA margin around 11.5% and free cash flow around EUR 0.9 billion. Productivity initiatives delivered EUR 188 million in savings during Q3.

Philips (NYSE: PHG) and Medtronic Neurovascular announced a strategic advocacy partnership to improve stroke care access globally. Both companies joined the newly established World Stroke Organization (WSO) Advocacy Coalition, focusing on three key areas: raising public awareness of stroke symptoms, improving treatment access, and leveraging technology for integrated care systems.

The partnership addresses a critical health issue affecting 12 million people annually, with direct and indirect costs estimated at USD 900 billion, expected to double in 25 years. The collaboration aims to develop a global network of comprehensive stroke care centers and will be highlighted at the upcoming World Stroke Congress in Abu Dhabi.

Philips is showcasing its latest cardiology innovations at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting from October 27-30 in Washington D.C. The company's portfolio integrates artificial intelligence into imaging systems and software, along with specialized diagnostic and therapeutic devices to support complex procedures.

Key advancements include:

• AI-enabled cardiovascular ultrasound platform for structural heart disease diagnosis
• Intravascular ultrasound (IVUS) for improved patient outcomes in coronary interventions
• Instantaneous free-ratio (iFR) for physiologic measurement during PCI
• 3D Intracardiac Echocardiography (ICE) catheter for structural heart disease procedures
• EchoNavigator 4.0 for advanced 3D heart modeling and live fusion imaging
• Laser System for coronary and peripheral atherectomy and lead extraction
• IntraSight platform for streamlined interventional procedures

Philips will also host educational sessions and hands-on trainings at their Engagement Hub during the event.

OMNIVISION and Philips have partnered to develop the world's first in-cabin connected well-being monitoring solution for automotive applications. The prototype, which will be demonstrated at AutoSens Europe in Barcelona from October 8-10, 2024, combines OMNIVISION's OX05B1S CMOS image sensor with Philips' vital signs camera software for automotive use.

The system monitors vital signs such as pulse and breathing rate, potentially enabling customization of comfort settings while driving. This data could be used to adapt media, climate, lighting, seating, engine modes, and more. The solution aims to add value for automotive consumers and shorten time to market for tier-one automotive OEMs.

OMNIVISION's OX05B1S is a 5-megapixel RGB-IR backside illuminated global shutter sensor featuring Nyxel® technology, which provides superior performance in low-light conditions. An AI-enabled OAX4600 image signal processor handles data processing for the med-tech system.

Royal Philips (NYSE: PHG, AEX: PHIA) announced significant greenhouse gas (GHG) emissions reduction results from collaborations with healthcare organizations worldwide. Key achievements include:

• Jackson Health System (US): 47% projected reduction in CO2e emissions
• Champalimaud Foundation (Portugal): 24% emissions reduction per exam in radiology and nuclear medicine
• Rennes University Hospital (France): Identified opportunities to reduce cath lab emissions
• County Durham and Darlington NHS Foundation Trust (UK): Developed a sustainability blueprint for ICU

Philips conducted comprehensive life cycle assessments (LCA) to help hospitals reduce their carbon footprint while enhancing patient care and operational efficiency. The company aims to improve the health and well-being of 2 billion people per year by 2025, including 300 million in underserved communities.